TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22305

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aspirin (600 mg in 1 dl of isotonic saline)
Number of subjects: 5
Study: 30343874

Group type: EXPERIMENTAL
Intervention: Sleep-promoting interventions
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual nursing care overnight
Number of subjects: 144
Study: 28045625

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy (anastrozole, exemestane, or letrozole)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Neoadjuvant aromatase inhibitor therapy
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 341
Study: 26204566

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) of the motor cortex (C3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 23795311

Group type: EXPERIMENTAL
Intervention: High intensity navigation services
Number of subjects: 835

Group type: COMPARATOR
Intervention: Low intensity navigation services
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Public insurance patients
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Neighbor Island patients
Number of subjects: 835
Study: 20707872

Group type: EXPERIMENTAL
Intervention: Dental health program including fluoride varnish applied twice per year for 2 years, advocacy for water consumption and daily tooth cleaning with toothpaste, community dental health promotion, and training for primary health care workers in preventive dental care.
Number of subjects: 666
Study: 19539184

Group type: EXPERIMENTAL
Intervention: Oral protein supplementation during hemodialysis and peritoneal dialysis
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no protein supplementation)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Oral protein supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both treatment groups (protein supplementation and control)
Number of subjects: 49
Study: 16894061

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15327558

Group type: EXPERIMENTAL
Intervention: HP cream and adapalene 0.1% gel (group HP + A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: BP cream and adapalene 0.1% gel (group BP + A)
Number of subjects: 52
Study: 11009278

Group type: EXPERIMENTAL
Intervention: Enoxaparin low molecular weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study: 9015035

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (6 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral dexamethasone (8 mg)
Number of subjects: 11
Study: 8112199

Group type: EXPERIMENTAL
Intervention: DHEP plaster
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 60
Study: 3526143

Group type: EXPERIMENTAL
Intervention: Ganglioside therapy (Cronassial, 40 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study: 31144070

Group type: EXPERIMENTAL
Intervention: Exercise associated with active PBM (808 nm, 100 mW, 7 points each side, 56 J total)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exercise associated with placebo PBM
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Active PBM group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo PBM group
Number of subjects: 62
Study: 31091576

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + Propofol (SP group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + Propofol (CP group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dexmedetomidine + Sevoflurane (SS group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dexmedetomidine + Sevoflurane (CS group)
Number of subjects: 200
Study: 28273855

Group type: EXPERIMENTAL
Intervention: Korean black raspberry (KBR) consumption for four weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline urinary glycine and N-phenylacetylglycine (PAG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline urinary adenine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-metabolite set (glycine and PAG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leave-one-out cross-validation
Number of subjects: 0
Study: 25956910

Group type: EXPERIMENTAL
Intervention: Academic detailing (AD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study: 23089290

Group type: EXPERIMENTAL
Intervention: Distributional information with strong category cues and robust category learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distributional information with sparser cues and consistent gaps
Number of subjects: 0
Study: 21074334

Group type: EXPERIMENTAL
Intervention: Image-guided radiation therapy (IGRT) using intraprostatic fiducials and Varian's Offline Review image analysis package.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IGRT credentialing process across multiple sites.
Number of subjects: 0
Study: 19200695

Group type: EXPERIMENTAL
Intervention: Manual-based psychotherapy
Number of subjects: 80
Study: 16686556

Group type: EXPERIMENTAL
Intervention: Rhythmic gymnastics program (16 weeks, 3 lessons per week, 40 minutes each)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (regular school schedule)
Number of subjects: 29
Study: 15471831

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET
Number of subjects: 37
Study: 11889646

Group type: EXPERIMENTAL
Intervention: Pain descriptors and indexes from the Italian Pain Questionnaire
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Self-evaluation of quality of life (QOL) from a categorical scale
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Self-assessed anxiety and/or depression
Number of subjects: 332
Study: 10771818

Group type: EXPERIMENTAL
Intervention: Bilirubin crystals in neutrophils (CP) in cases of septicaemia
Number of subjects: 143

Group type: COMPARATOR
Intervention: Bilirubin crystals in neutrophils (CP) in cases of Haemolytic Disease of Newborn (HDN)
Number of subjects: 143
Study: 7890434

Group type: EXPERIMENTAL
Intervention: Continuous hemodiafiltration
Number of subjects: 72
Study: 3213064

Group type: EXPERIMENTAL
Intervention: Physical therapy for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical therapy for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatments (Acupuncture and Physical Therapy)
Number of subjects: 0
Study: 30371925

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg orally)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg IV bolus, followed by 0.5 µg/kg/h infusion)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Pregabalin and Dexmedetomidine (combined treatment)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 124
Study: 27411760

Group type: EXPERIMENTAL
Intervention: Music intervention during non-stress test (NST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Music intervention during NST
Number of subjects: 60
Study: 24412145

Group type: EXPERIMENTAL
Intervention: CPM device on and moving from the immediate post-operative period
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CPM device on and stationary at 90 degree flexion for the first night and then moving throughout the rest of their stay
Number of subjects: 160

Group type: COMPARATOR
Intervention: No CPM
Number of subjects: 160
Study: 21884017

Group type: EXPERIMENTAL
Intervention: etoricoxib 60 or 90 mg daily
Number of subjects: 34701

Group type: COMPARATOR
Intervention: diclofenac 150 mg daily
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: Baseline diastolic blood pressure (DBP)
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: Change in blood pressure from months 0 to 4
Number of subjects: 34701
Study: 20099399

Group type: EXPERIMENTAL
Intervention: Protease inhibitor strategy
Number of subjects: 903

Group type: COMPARATOR
Intervention: NNRTI strategy
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Cumulative adherence
Number of subjects: 903
Study: 18164829

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) + thalidomide
Number of subjects: 156

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 156
Study: 15959841

Group type: EXPERIMENTAL
Intervention: NT 201
Number of subjects: 304

Group type: COMPARATOR
Intervention: BOTOX
Number of subjects: 304
Study: 11738688

Group type: EXPERIMENTAL
Intervention: Monothermal warm air caloric test (MWAT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Bithermal air caloric test (BAT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Monothermal cold air caloric test (MCAT)
Number of subjects: 86
Study: 9737815

Group type: EXPERIMENTAL
Intervention: Oral eprosartan (300 mg) under fasting conditions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral eprosartan (300 mg) following a high-fat breakfast
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous eprosartan (20 mg)
Number of subjects: 18
Study: 8296748

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg every day
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 3046309

Group type: EXPERIMENTAL
Intervention: Lactoovovegetarian diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seventh-day Adventist vegetarians
Number of subjects: 0
Study: 31407238

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 0
Study: 29136037

Group type: EXPERIMENTAL
Intervention: IV VRC01 (40 mg/kg loading dose followed by five 20 mg/kg doses every 4 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IV VRC01 (30 mg/kg doses every 8 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IV VRC01 (10 mg/kg doses every 8 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: SC VRC01 (5 mg/kg every 2 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 23966118

Group type: EXPERIMENTAL
Intervention: Increased time awake
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reduced time spent in stage 1 sleep
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total sleep time
Number of subjects: 40
Study: 21167685

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Casein formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Number of subjects: 31
Study: 19183414

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 109
Study: 17401538

Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX) 4 mg twice a day for 4 days preceded by 2 mg twice a day for 2 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX)
Number of subjects: 12
Study: 15527198

Group type: EXPERIMENTAL
Intervention: Qi-therapy (nine sessions over two menstrual cycles)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 46
Study: 11137652

Group type: EXPERIMENTAL
Intervention: Ambisome (amphotericin B lipid complex) at a dose of 15mg/kg body weight infused over 2h as a single dose
Number of subjects: 34

Group type: COMPARATOR
Intervention: amphotericin B deoxycholate at a dose of 1mg/kg body infused for 2h for 20 days
Number of subjects: 34
Study: 9754723

Group type: EXPERIMENTAL
Intervention: Ranitidine (acid suppression)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study: 7812019

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation after proximal femoral fracture
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 200
Study: 2684085

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride plus clinical management
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo plus clinical management
Number of subjects: 250
Study: 31826326

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (6 times a week)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (3 times a week)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Daily Trial)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Nocturnal Trial)
Number of subjects: 332
Study: 30611722

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided treatment
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: NT-proBNP reduction
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Achieving NT-proBNP goal
Number of subjects: 268
Study: 29241487

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2947

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2947
Study: 25938245

Group type: EXPERIMENTAL
Intervention: Computerized spatial navigation training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 15
Study: 23216554

Group type: EXPERIMENTAL
Intervention: Psychosocial education program (4 sessions, 120 minutes each, once a week for 4 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine program at private education and rehabilitation centre (control group)
Number of subjects: 75
Study: 21462185

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed circumcision (control)
Number of subjects: 100
Study: 19022794

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 16469857

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich food (cocoa beverage)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Polyphenol-free food (milk)
Number of subjects: 36
Study: 16183679

Group type: EXPERIMENTAL
Intervention: Activated recombinant factor VII (rFVIIa)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12825133

Group type: EXPERIMENTAL
Intervention: Interferon alpha2b + Cyclosporin A (200 mg daily for the first 4 weeks and 100 mg daily for the following 20 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interferon alpha2b + Cyclosporin A
Number of subjects: 120

Group type: COMPARATOR
Intervention: Interferon alpha2b (monotherapy)
Number of subjects: 120
Study: 9974084

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 7780066

Group type: EXPERIMENTAL
Intervention: Red Rubber (RR) double-lumen tubes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Polyvinyl-Chloride (PVC) double-lumen tubes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both RR and PVC groups
Number of subjects: 21
Study: 1699704

Group type: EXPERIMENTAL
Intervention: Fluosol DA-20% (FDA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Crystalloid/hydroxyethyl starch (CHS)
Number of subjects: 46
Study: 362094

Group type: EXPERIMENTAL
Intervention: Topical glycopyrrolate (0.5% and 1.0%)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Topical scopolamine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Commercial topical antiperspirants
Number of subjects: 129
Study: 29983135

Group type: EXPERIMENTAL
Intervention: Linseed diet (LS) containing 10% whole linseed, fed for 40 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Linseed diet (LS) containing 10% whole linseed, fed for 75 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Linseed diet (LS) containing 10% whole linseed, fed for 120 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control diet (CO) with no supplemental fat, fed for 40 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control diet (CO) with no supplemental fat, fed for 75 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control diet (CO) with no supplemental fat, fed for 120 days
Number of subjects: 54
Study: 26011652

Group type: EXPERIMENTAL
Intervention: BHOMA intervention
Number of subjects: 0
Study: 25563737

Group type: EXPERIMENTAL
Intervention: Whey protein-enriched preload beverage (300 ml, 1300 kJ, 45 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Maltodextrin carbohydrate-enriched preload beverage
Number of subjects: 18
Study: 23926573

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 (10 mg, 20 mg, or 30 mg, twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine (10 mg/d during week 1; 15 mg/d after week 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (6 weeks followed by 6 weeks of olanzapine, 15 mg/d)
Number of subjects: 0
Study: 22136031

Group type: EXPERIMENTAL
Intervention: 2 Hz continuous wave (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 Hz continuous wave (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz (Group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group D
Number of subjects: 80
Study: 19594251

Group type: EXPERIMENTAL
Intervention: Multicultural training program
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Monocultural training program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Summer research training programs (both multicultural and monocultural)
Number of subjects: 86
Study: 16738292

Group type: EXPERIMENTAL
Intervention: Nerve stimulator guided pudendal nerve block
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 80
Study: 15301641

Group type: EXPERIMENTAL
Intervention: Coping Power child component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full Coping Power Program with parent and child components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 11051229

Group type: EXPERIMENTAL
Intervention: Liquid preparation of DFMO at daily dose 0.5 gram/m2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tablet preparation of DFMO at daily dose 0.5 gram/m2
Number of subjects: 10
Study: 9349514

Group type: EXPERIMENTAL
Intervention: Fine-needle capillary biopsy (FNCB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fine-needle aspiration biopsy (FNAB)
Number of subjects: 50
Study: 7693506

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg via metered dose inhaler)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 6
Study: 4041951

Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes before premedication
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-smoking group (not allowed to smoke)
Number of subjects: 74
Study: 30794237

Group type: EXPERIMENTAL
Intervention: Compression bandage
Number of subjects: 51
Study: 28472255

Group type: EXPERIMENTAL
Intervention: Intensified antituberculosis regimen (15 mg/kg/day rifampicin and 20 mg/kg/day levofloxacin for the first 8 weeks)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Standard 9-month antituberculosis regimen (10 mg/kg/day rifampicin)
Number of subjects: 322
Study: 25937380

Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: AirTraq
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Miller Laryngoscope
Number of subjects: 102
Study: 23871105

Group type: EXPERIMENTAL
Intervention: Maternal diet quality
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Child diet quality
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 177
Study: 21190026

Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC)
Number of subjects: 463

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 463
Study: 19222654

Group type: EXPERIMENTAL
Intervention: Honey (Medihoney)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 105
Study: 17133774

Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg twice daily on day 1 followed by 40 mg once daily on days 2‐7)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Diclofenac (75 mg twice daily)
Number of subjects: 202
Study: 12642564

Group type: EXPERIMENTAL
Intervention: Self-reported home safety practices (using smoke alarms, stair gates, syrup of ipecac)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11227970

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 154

Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 154
Study: 9513096

Group type: EXPERIMENTAL
Intervention: Dyract with Prime and Bond 2.0 (Group 2)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Compoglass with Syntac Single Component (Group 4)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Dyract with Dyract‐PSA primer (Group 1)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Compoglass with SCA primer (Group 3)
Number of subjects: 4
Study: 7845561

Group type: EXPERIMENTAL
Intervention: Motor learning tasks including a three-dimensional motor problem and two standard precision tests.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (16 subjects).
Number of subjects: 20